Interferon-beta-1-b (IFN-B) decreases induced nitric oxide (NO) production by a human astrocytoma cell line

Journal of Neuroimmunology

Volumn 82, Issue 2, 1998, Pages 133-139

  Guthikonda, Prasanti ^a   Baker, Jeffery ^b   Mattson, David H ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A172, human astrocytoma cell line; Astrocytes; Cytokines; Dexamethasone; Interferon beta; Multiple sclerosis; Nitric oxide

Indexed keywords

AMINOGUANIDINE; CYTOKINE; DEXAMETHASONE; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; ASTROCYTOMA CELL; CONTROLLED STUDY; DEMYELINATION; DRUG MECHANISM; ENZYME INDUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TUMOR CELL LINE;

ASTROCYTOMA; CYTOKINES; DEXAMETHASONE; ENZYME INHIBITORS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INTERFERON-BETA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; TUMOR CELLS, CULTURED;

EID: 0031917260     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00172-0     Document Type: Article

References (70)

1. Albina J.E., Henry W.L. Jr. Suppression of lymphocyte proliferation through the nitric oxide synthesizing pathway. J. Surg. Res. 50:1991;403-409.
2. Arnason B.G.W. Interferon beta in multiple sclerosis. Neurology. 43:1993;641-643.
3. Bö L., Dawson T.M., Wesselingh S., Mörk S., Choi S., Kong P.A., Hanley D., Trapp B.D. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36:1994;778-786.
4. Brosnan C.F., Battistini L., Raine C.S., Dickson D.W., Casadevall A., Lee S.C. Reactive nitrogen intermediates in human neuropathology: an overview. Dev. Neurosci. 16:1994;152-161.
5. Brosnan C.F., Cannella B., Battistini L., Raine C.S. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology. 45:1995;S16-S21.
6. Cetkovic-Cvrlje M., Sandler S., Eizirik D.L. Nicotinamide and dexamethasone inhibit interleukin-1-induced nitric oxide production by RINm5F cells without decreasing messenger ribonucleic acid expression for nitric oxide synthase. Endocrinology. 133:1993;1739-1743.
7. Chesrown S.E., Monnier J., Visner G., Nick H.S. Regulation of inducible nitric oxide synthase mRNA levels by LPS, IFN-γ, TGF-β, and IL-10 in murine macrophage cell lines and rat peritoneal macrophages. Biochem. Biophys. Res. Comm. 200:1994;126-134.
8. Connelly J.F. Interferon beta for multiple sclerosis. Ann. Pharmaco. 28:1994;610-616.
9. Corbett J.A., Tilton R.G., Chang K., Hasan K.S., Ido Y., Wang J.L., Sweetland M.A., Lancaster J.R. Jr., Williamson J.R., McDaniel M.L. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 41:1992;552-556.
10. Cross A.H., Misko T.P., Lin R.F., Hickey W.F., Trotter J.L., Tilton R.G. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J. Clin. Inv. 93:1994;2684-2690.
11. Cunha F.Q., Moncada S., Liew F.Y. Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-γ in murine macrophages. Biochem. Biophys. Res. Comm. 182:1992;1155-1159.
12. Curran R.D., Billiar T.R., Stuehr D.J., Ochoa J.B., Harbrecht B.G., Flint S.G., Simmons R.L. Multiple cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis. Ann. Surg. 212:1990;462-471.
13. 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-γ J. Immunol. 145:1990;940-944.
14. Di Rosa M., Radomski M., Carnuccio R., Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem. Biophys. Res. Comm. 172:1990;1246-1252.
15. Evans T.G., Thai L., Granger D.L., Hibbs J.B. Jr. Effect of in vivo inhibition of nitric oxide production in murine Leishmaniasis. J. Immunol. 151:1993;907-915.
16. Farrell A.J., Blake D.R., Palmer R.M., Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann. Rheum. Dis. 51:1992;1219-1222.
17. Fu Y., Blankenhorn E.P. Nitric oxide-induced anti-mitogenic effects in high and low responder rat strains. J. Immunol. 148:1992;2217-2222.
18. Gazzinelli R.T., Oswald I.P., James S.L., Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ-activated macrophages. J. Immunol. 148:1992;1792-1796.
19. Geller D.A., Lowenstein C.J., Shapiro R.A., Nussler A.K., Di Silvio M., Wang S.C., Nakayama D.K., Simmons R.L., Snyder S.H., Billiar T.R. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc. Nat. Acad. Sci. USA. 90:1993;3491-3495.
20. Goodkin D.E. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. Wes. J. Med. 161:1994;292-298.
21. Goodman A., McFarlin D.E. Multiple Sclerosis. Curr. Neurol. 7:1987;91-128.
22. 15N ]nitrate in biological fluids Analyt. Biochem. 126:1982;131-138.
23. Gregory S.H., Wing E.J., Hoffman R.A., Simmons R.L. Reactive nitrogen intermediates suppress the primary immunologic response to Listeria. J. Immunol. 150:1993;2901-2909.
24. Hafler D.A., Weiner H.L. MS: a CNS and systemic autoimmune disease. Immunol. Today. 10:1989;104-107.
25. Hintzen R.Q., Polman C.H., Lucas C.J., van Lier R.A.W. Multiple sclerosis: immunological findings and possible implications for therapy. J. Neuroimmunol. 39:1992;1-10.
26. Hoffman R.A., Langrehr J.M., Billiar T.R., Curran R.D., Simmons R.L. Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J. Immunol. 145:1990;2220-2226.
27. Hofman F.M., Hinton D.R., Johnson K., Merrill J.E. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170:1989;607-612.
28. Hokari A., Zeniya M., Esumi H. Cloning and functional expression of human inducible nitric oxide synthase (NOS) cDNA from a glioblastoma cell line A-172. J. Biochem. 116:1994;575-581.
29. Janabi N., Chabrier S., Tardieu M. Endogenous nitric oxide activates prostaglandin F2 alpha production in human microglia but not astrocytes. J. Immunol. 157:1996;2129-2135.
30. Jiang H., Milo R., Swoveland P., Johnson K.P., Panitch H., Dhib-Jalbut S. Interferon β-1b reduces interferon γ-induced antigen-presenting capacity of human glial and B cells. J. Neuroimmunol. 61:1995;17-25.
31. Johnson A.W., Land J.M., Thompson E.J., Bolanos J.P., Clark J.B., Heales S.J.R. Evidence for increased nitric oxide production in multiple sclerosis. J. Neurol. Neurosurg. Psych. 58:1995;107.
32. Kawabe T., Isobe K.-I., Hasegawa Y., Nakashima I., Shimokata K. Immunosuppressive activity induced by nitric oxide in culture supernatant of activated rat alveolar macrophages. Immunol. 76:1992;72-78.
33. Kolb H., Kiesel U., Kröncke K.-D., Kolb-Bachofen V. Suppression of low dose streptozotocin induced diabetes in mice by administration of a nitric oxide synthase inhibitor. Life Sciences. 49:1991;PL213-PL217.
34. Kolb H., Kolb-Bachofen V. Nitric oxide: a pathogenic factor in autoimmunity. Immunol. Today. 13:1992;157-160.
35. Lancaster J.R. Jr. Nitric oxide in cells. American Scientist. 80:1992;248-259.
36. Langrehr J.M., Hoffman R.A., Lancaster J.R. Jr., Simmons R.L. Nitric oxide - a new endogenous immunomodulator. Transplantation. 55:1993;1205-1212.
37. Lee S.C., Dickson D.W., Liu W., Brosnan C.F. Induction of nitric oxide synthase activity in human astrocytes by interleukin-1β and interferon-γ J. Neuroimmunol. 46:1993;19-24.
38. Liew F.Y. Regulation of nitric oxide synthesis in infectious and autoimmune diseases. Immunol. Lett. 43:1994;95-98.
39. Liew F.Y. Regulation of lymphocyte functions by nitric oxide. Curr. Opin. Immunol. 7:1995;396-399.
40. Lipton S.A., Choi Y.-B., Pan Z.-H., Lie S.Z., Chen H.-S.V., Sucher N.J., Loscalzo J., Singel D.J., Stamler J.S. A redox-based mechanism for the neuroprotective and neuro-destructive effects of nitric oxide and related nitroso-compounds. Nature. 364:1993;626-632.
41. Lowenstein C.J., Snyder S.H. Nitric oxide, a novel biologic messenger. Cell. 70:1992;705-707.
42. Lukic M.L., Stosic-Grujicic S., Ostojic N., Chan W.L., Liew F.Y. Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in mice. Biochem. Biophys. Res. Comm. 178:1991;913-920.
43. Marletta M.A. Nitric oxide synthase structure and mechanism. J. Biol. Chem. 268:1993;12231-12234.
44. Merrill J.E., Ignarro L.J., Sherman M.P., Melinek J., Lane T.E. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151:1993;2132-2141.
45. Mills C.D. Molecular basis of 'suppressor macrophages' - arginine metabolism via the nitric oxide synthetase pathway. J. Immunol. 146:1991;2719-2723.
46. Misko T.P., Moore W.M., Kasten T.P., Nickols G.A., Corbett J.A., Tilton R.G., McDaniel M.L., Williamson J.R., Currie M.G. Selective inhibition of the inducible nitric synthase by aminoguanidine. Eur. J. Pharm. 233:1993;119-125.
47. Mitrovic B., Ignarro L.J., Montestruque S., Smoll A., Merrill J.E. Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro. Neuroscience. 61:1994;575-585.
48. ++-calmodulin-independent NO-synthase. Biochem. Biophys. Res. Comm. 191:1993;327-334.
49. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharm. Rev. 43:1991;109-142.
50. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6:1992;3051-3064.
51. Noronha A., Toscas A., Jensen M.A. Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis. Ann. Neurol. 31:1992;103-106.
52. Noronha A., Toscas A., Jensen M.A. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J. Neuroimmunol. 46:1993;145-154.
53. Nussler A.K., Billiar T.R. Inflammation, immunoregulation, and inducible nitric oxide synthase. J. Leukoc. Biol. 54:1993;171-178.
54. O'Connor K.J., Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase and the related cell damage in adenocarcinoma cells. Biochim. Biophys. Acta. 1097:1991;227-231.
55. Okuda Y., Nakatsuji Y., Fujimura H., Esumi H., Ogura T., Yanagihara T., Sakoda S. Expression of the inducible isoform of nitric oxide synthase in the central nervous system of mice correlates with the severity of actively induced experimental allergic encephalomyelitis. J. Neuroimmunol. 62:1995;103-112.
56. Paty, D.W., Li, D.K.B., the UBC MS/MRI Study Group and the IFNβ Multiple Sclerosis Study Group, 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 43, 662-667.
57. Porrini A.M., Gambi D., Reder A.T. Interferon effects on interleukin-10 secretion - mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J. Neuroimmunol. 61:1995;27-34.
58. Rees D.D., Palmer R.M.J., Hodson H.F., Moncada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br. J. Pharmacol. 96:1989;418-424.
59. Radomski M.W., Palmer R.M.J., Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Nat. Acad. Sci. USA. 87:1990;10043-10047.
60. Sakai N., Milstien S. Availability of tetrahydrobiopterin is not a factor in the inability to detect nitric oxide production by human macrophages. Biochem. Biophys. Res. Comm. 193:1993;378-383.
61. Schleifer K.W., Mansfield J.M. Suppressor macrophages in African Trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins. J. Immunol. 151:1993;5492-5503.
62. Schmidt H.H.W., Walter U. NO at work. Cell. 78:1994;919-925.
63. Schneeman M., Schoedon G., Hofer S., Blau N., Guerrero L., Schaffner A. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J. Inf. Dis. 167:1993;1358-1363.
64. Sherman M.P., Griscavage J.M., Ignarro L.J. Nitric oxide-mediated neuronal injury in multiple sclerosis. Med. Hypotheses. 39:1992;143-146.
65. Simmons M.L., Murphy S. Induction of nitric oxide synthase in glial cells. J. Neurochem. 59:1992;897-905.
66. Traugott U., Lebon P. Multiple sclerosis: involvement of interferons in lesion pathogenesis. Ann. Neurol. 24:1988;243-251.
67. Whitaker J.N. Rationale for immunotherapy in multiple sclerosis. Ann. Neurol. 36:1994;S103-S107.
68. Woodroofe M.N. Cytokine production in the central nervous system. Neurology. 45:1995;S6-S10.
69. Zembala M., Siedlar M., Marcinkiewicz J., Pryjma J. Human monocytes are stimulated for nitric oxide release in vitro by some tumor cells but not by cytokines and lipopolysaccharide. Eur. J. Immunol. 24:1994;435-439.
70. Zielasek J., Tausch M., Toyka K.V., Hartung H.P. Production of nitrite by neonatal rat microglial cells/brain macrophages. Cell. Immunol. 141:1992;111-120.